首页> 外文期刊>Journal of artificial organs: The official journal of the Japanese Society for Artificial Organs >A heart transplant candidate with severe pulmonary hypertension and extremely high pulmonary vascular resistance
【24h】

A heart transplant candidate with severe pulmonary hypertension and extremely high pulmonary vascular resistance

机译:患有严重肺动脉高压和极高肺血管阻力的心脏移植候选人

获取原文
获取原文并翻译 | 示例
           

摘要

Fixed pulmonary hypertension (PH) is a contraindication for heart transplantation (HTx). Several studies showed that use of a left ventricular assist device (LVAD) in patients with fixed PH who were initially deemed ineligible for HTx effectively decreased pulmonary arterial pressure (PAP), thus permitting HTx. We recently encountered a candidate for HTx who had severe PH with extremely high pulmonary vascular resistance (PVR). A 27-year-old female who had been diagnosed with dilated-phase hypertrophic cardiomyopathy and who was approved for HTx at age 25 was referred to our institute because of severe fatigability with moderate dyspnea even at rest due to severe bilateral heart failure. Despite continuous inotrope infusion, the patient's symptoms were not relieved. Right heart catheterization (RHC) disclosed a PAP of 62/40 mmHg with severely reduced cardiac output (1.8 l/min). A PVR of 15.9 Wood units suggested progressive worsening of left ventricular function with almost irreversible remodeling of the pulmonary vasculature, and the patient was thought to be contraindicated for HTx. Following 3 weeks of aggressive medical treatment, repeat RHC demonstrated PVR lowering to 8.16 Wood units. This suggested it was likely that PVR could be reversed, and the patient underwent LVAD implantation. RHC performed after LVAD implantation showed a fall in PVR from the initial, extremely high measurement of 15.9 Wood units to 3.4 Wood units at 2 months postoperatively, and to 2.2 Wood units at 1 year. The patient is currently awaiting HTx with favorable LVAD support.
机译:固定性肺动脉高压(PH)是心脏移植(HTx)的禁忌症。几项研究表明,最初被认为不适合使用HTx的固定PH患者使用左心室辅助装置(LVAD)可有效降低肺动脉压(PAP),从而允许使用HTx。我们最近遇到了HTx的候选人,他患有严重的PH和极高的肺血管阻力(PVR)。一名27岁的女性被诊断患有扩张型肥厚型心肌病,并在25岁时被批准接受HTx治疗,由于严重的易疲劳性和中等的呼吸困难,甚至在休息时由于严重的双侧心力衰竭而被转诊到我所。尽管持续输注了输卵管,但患者的症状并未缓解。右心导管检查(RHC)揭示了PAP为62/40 mmHg,严重降低了心输出量(1.8 l / min)。 PVR为15.9伍德单位表示左心室功能逐渐恶化,肺血管系统几乎不可逆转地重塑,该患者被认为是HTx的禁忌症。经过3周的积极医疗,重复RHC显示PVR降低至8.16伍德单位。这表明PVR很可能会逆转,并且患者接受了LVAD植入。 LVAD植入后进行的RHC显示,PVR从最初的极高测量值(术后1个月的15.9伍德单位降低到术后2个月的3.4伍德单位和1年的2.2伍德单位)下降。该患者目前正在等待LVAD支持良好的HTx。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号